Peptide nucleic acids as epigenetic inhibitors of HIV-1

Letters in Peptide Science

Volumn 10, Issue 3-4, 2003, Pages 269-286

  Sei, Shizuko ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

HIV gene target; HIV AIDS; peptide nucleic acids

Indexed keywords

ANTENNAPEDIA PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DNA; INDINAVIR; MESSENGER RNA; PEPTIDE; PEPTIDE NUCLEIC ACID; PROTEINASE INHIBITOR; TRANSPORTAN; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; DNA RESPONSIVE ELEMENT; DRUG DISTRIBUTION; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVITY; EPIDEMIC; EPIGENETICS; GENE EXPRESSION; GENE INTERACTION; GENE SEQUENCE; GENE TARGETING; GENE TRANSFER; GENETIC DISORDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VIVO STUDY; LIFE CYCLE; MICROINJECTION; MOLECULAR MECHANICS; MOLECULE; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PREVALENCE; PROTEIN MODIFICATION; RNA TRANSLATION; TECHNOLOGY; TOXICITY; VIRION; VIRUS INHIBITION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 11144281332     PISSN: 09295666     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02484563     Document Type: Article

References (172)

1. Masur, H., Michelis, M.A., Greene, J.B. et al., An outbreak of community-acquired Pneumocystis carinii pneumonia: Initial manifestation of cellular immune dysfunction. N. Engl. J. Med., 305 (1981) 1431.
2. Gottlieb, M.S., Schroff, R., Schanker, H.M. et al., Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med., 305 (1981) 1425.
3. Division of HIV/AIDS Prevention National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Vol. 10. U.S. Department of Health and Human Services, Public Health Service, Atlanta, 1998, 1.
4. Aalen, O.O., Farewell, V.T., De Angelis, D., Day, N.E. and Gill, O.N., New therapy explains the fall in AIDS incidence with a substantial rise in number of persons on treatment expected. AIDS, 13 (1999) 103.
5. Boden, D., Hurley, A., Zhang, L. et al., HIV-1 drug resistance in newly infected individuals. JAMA, 282 (1999) 1135.
6. Little, S.J., Daar, E.S., D'Aquila, R.T. et al., Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA, 282 (1999) 1142.
7. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ, 322 (2001) 1087.
8. Larder, B.A., Hertogs, K., Bloor, S. et al., Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS, 14 (2000) 1943.
9. For a detailed review on HIV-1 and its replication cycle see Human immunodeficiency viruses and their replication. In: D.M. Knipe and P.M. Howley (Eds.) Fields Virology. Lippincott Williams and Wilkins, Philadelphia, 2001.
10. Berger, E.A., Murphy, P.M. and Farber, J.M., Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu. Rev. Immunol., 17 (1999) 657.
11. Kaplan, A.H., Manchester, M. and Swanstrom, R., The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J. Virol., 68 (1994) 6782.
12. Mitsuya, H., Weinhold, K.J., Furman, P.A. et al., 3′-Azido- 3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic vims type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA, 82 (1985) 7096.
13. Yarchoan, R., Klecker, R.W., Weinhold, K.J. et al., Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet, 1 (1986) 575.
14. Mitsuya, H., Jarrett, R.F., Matsukura, M. et al., Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2′,3′-dideoxynucleosides in vitro. Proc. Natl. Acad. Sci. USA, 84 (1987) 2033.
15. Yarchoan, R., Mitsuya, H., Thomas, R.V. et al., In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine. Science, 245 (1989) 412.
16. Oberlin, E., Amara, A., Bachelerie, F. et al., The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 (published erratum appears in Nature, 21 November 1996, 384 (6606) 288), Nature, 382 (1996) 833.
17. Doranz, B.J., Grovit-Ferbas, K., Sharron, M.P. et al., A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med., 186 (1997) 1395.
18. Murakami, T., Nakajima, T., Koyanagi, Y. et al., A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J. Exp. Med., 186 (1997) 1389.
19. Simmons, G., Clapham, P.R., Picard, L. et al., Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science, 276 (1997) 276.
20. Donzella, G.A., Schols, D., Lin, S.W. et al., AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. (1998) 472.
21. Gong, W., Howard, O.M., Tuipin, J.A. et al., Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication. J. Biol. Chem., 273 (1998) 4289.
22. Kilby, J.M., Hopkins, S., Venetta, T.M. et al., Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med., 4 (1998) 1302.
23. Pilcher, C.D., Eron Jr., J.J., Ngo, L. et al., Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual. AIDS, 13 (1999) 2171.
24. Puras Lutzke, R.A., Eppens, N.A., Weber, P.A., Houghten, R.A. and Plasterk, R.H., Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library. Proc. Natl. Acad. Sci. USA, 92 (1995) 11456.
25. Eich, E., Pertz, H., Kaloga, M. et al., (-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase. J. Med. Chem., 39 (1996) 86.
26. Mazumder, A., Neamati, N., Ojwang, J.O., Sunder, S., Rando, R.F. and Pommier, Y., Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry, 35 (1996) 13762.
27. Zhao, H., Neamati, N., Hong, H. et al., Coumarin-based inhibitors of HIV integrase. J. Med. Chem., 40 (1997) 242.
28. Zhao, H., Neamati, N., Sunder, S. et al., Hydrazide-containing inhibitors of HIV-1 integrase. J. Med. Chem., 40 (1997) 937.
29. Artico, M., Di Santo, R., Costi, R. et al., Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation, and molecular modeling. J. Med. Chem., 41 (1998) 3948.
30. Farnet, C.M., Wang, B., Hansen, M. et al., Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism. Antimicrob. Agents Chemother., 42 (1998) 2245.
31. Neamati, N., Hong, H., Owen, J.M. et al., Salicylhydrazine-containing inhibitors of HIV-1 integrase: Implication for a selective chelation in the integrase active site. J. Med. Chem., 41 (1998) 3202.
32. Molteni, Y. Rhodes, D., Rubins, K., Hansen, M., Bushman, F.D. and Siegel, J.S., A new class of HIV-1 integrase inhibitors: The 3,3,3′, 3′-tetramethyl-1,1′-spirobi(indan)-5,5′,6,6′-tetrol family. J. Med. Chem., 43 (2000) 2031.
33. Reddy, M.V., Rao, M.R., Rhodes, D. et al., Lamellarin alpha 20-sulfate, an inhibitor of HIV-1 integrase active against HIV-1 virus in cell culture. J. Med. Chem., 42 (1999) 1901.
34. Hazuda, D.J., Felock, P., Witmer, M. et al., Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science, 287 (2000) 646.
35. Rice, W.G., Schaeffer, C.A., Harten, B. et al., Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds. Nature, 361 (1993) 473.
36. McDonnell, N.B., De Guzman, R.N., Rice, W.G., Turpin, J.A. and Summers, M.F., Zinc ejection as a new rationale for the use of cystamine and related disulfide-containing antiviral agents in the treatment of AIDS. J. Med. Chem., 40 (1997) 1969.
37. Rice, W.G., Baker, D.C., Schaeffer, C.A. et al., Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob. Agents Chemother., 41 (1997) 419.
38. Haubrich, R.H., Flexner, C., Lederman, M.M. et al., A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J. Infect. Dis., 172 (1995) 1246.
39. Dropulic, B. and Jeang, K.T., Gene therapy for human immunodeficiency virus infection: Genetic antiviral strategies and targets for intervention. Hum. Gene Ther., 5 (1994) 927.
40. Morgan, R.A., Genetic strategies to inhibit HIV. Mol. Med. Today, 5 (1999) 454.
41. Domburg, R. and Pomerantz, R.J., HIV-1 gene therapy: Promise for the future. Adv. Pharmacol., 49 (2000) 229.
42. Zamecnik, P.C., Goodchild, J., Taguchi, Y. and Sarin, P.S., Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc. Natl. Acad. Sci. USA, 83 (1986) 4143.
43. Matsukura, M., Zon, G., Shinozuka, K. et al., Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc. Natl. Acad. Sci. USA, 86 (1989) 4244.
44. Agrawal, S., Ikeuchi, T., Sun, D. et al., Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues. Proc. Natl. Acad. Sci. USA, 86 (1989) 7790.
45. Kinchington, D., Galpin, S., Jaroszewski, J.W., Ghosh, K., Subasinghe, C. and Cohen, J.S. A comparison of gag, pol and rev antisense oligodeoxynucleotides as inhibitors of HIV-1. Antiviral Res., 17 (1992) 53.
46. Lisziewicz, I., Sun, D., Klotman, M., Agrawal, S., Zamecnik, P. and Gallo, R., Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: An in vitro model for treatment. Proc. Natl. Acad. Sci. USA, 89 (1992) 11209.
47. Lisziewicz, J., Sun, D., Metelev, V., Zamecnik, P., Gallo, R.C. and Agrawal, S., Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates. Proc. Natl. Acad. Sci. USA, 90 (1993) 3860.
48. Lisziewicz, J., Sun, D., Weichold, F.F. et al., Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc. Natl. Acad. Sci. USA, 91 (1994) 7942.
49. Anazodo, M.I., Wainberg, M.A., Friesen, A.D. and Wright, J.A., Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome. J. Virol., 69 (1995) 1794.
50. Lisziewicz, J., Sun, D., Lisziewicz, A. and Gallo, R.C., Antitat gene therapy: A candidate for late-stage AIDS patients. Gene. Ther., 2 (1995) 218.
51. Kim, S.G., Hatta, T., Tsukahara, S. et al., Antiviral effect of phosphorothioate oligodeoxyribonucleotides complementary to human immunodeficiency virus. Bioorg. Med. Chem., 3 (1995) 49.
52. Weichold, F.F., Lisziewicz, J., Zeman, R.A. et al., Antisense phosphorothioate oligodeoxynucleotides alter HIV type 1 replication in cultured human macrophages and peripheral blood mononuclear cells. AIDS Res. Hum. Retroviruses, 11 (1995) 863.
53. Anazodo, M.I., Duta, E., Friesen, A.D. and Wright, J.A., Relative levels of inhibition of p24 gene expression by different 20-mer antisense oligonucleotide sequences targeting nucleotides +1129 to +1268 of the HIV-1 gag genome: An analysis of mechanism. Biochem. Biophys. Res. Commun., 229 (1996) 305.
54. Yamaguchi, K., Papp, B., Zhang, D., Ali, A.N., Agrawal, S. and Byrn, R.A., The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses, 13 (1997) 545.
55. Clinical trial results of GEM91 show activity against advance HIV. AIDS Patient Care STDS, 11 (1997) 290.
56. Stoddart, C.A., Rabin, L., Hincenbergs, M. et al., Inhibition of human immunodeficiency virus type 1 infection in SCID-hu Thy/Liv mice by the G-quartet-forming oligonucleotide, ISIS 5320. Antimicrob. Agents Chemother., 42 (1998) 2113.
57. Temsamani, J., Roskey, A., Chaix, C. and Agrawal, S., In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide. Antisense Nucl. Acids Drug Dev., 7 (1997) 159.
58. Baker, B.F. and Monia, B.P., Novel mechanisms for antisense-mediated regulation of gene expression. Biochim. Biophys. Acta, 1489 (1999) 3.
59. Wang, S. and Dolnick, B.J., Quantitative evaluation of intracellular sense: Antisense RNA hybrid duplexes. Nucl. Acids Res., 21 (1993) 4383.
60. Too, C.K., Rapid induction of Jak2 and Sp1 in T cells by phosphorothioate oligonucleotides. Antisense Nucl. Acid Drug Dev., 8 (1998) 87.
61. Mansky, L.M. and Temin, H.M., Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol., 69 (1995) 5087.
62. Patel, P.H. and Preston, B.D., Marked infidelity of human immunodeficiency virus type 1 reverse transcriptase at RNA and DNA template ends. Proc. Natl. Acad. Sci. USA, 91 (1994) 549.
63. Preston, B.D., Poiesz, B.J. and Loeb, L.A., Fidelity of HIV-1 reverse transcriptase. Science, 242 (1988) 1168.
64. Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M. and Ho, D.D., HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science, 271 (1996) 1582.
65. Goodenow, M., Huet, T., Saurin, W., Kwok, S., Sninsky, J. and Wain-Hobson, S., HIV-1 isolates are rapidly evolving quasispecies: Evidence for viral mixtures and preferred nucleotide substitutions. J. Acquir. Immune. Defic. Syndr., 2 (1989) 344.
66. -1 receiving combination therapy. JAMA, 286 (2001) 196.
67. Nielsen, P.E., Egholm, M., Berg, R.H. and Buchardt, O., Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science, 254 (1991) 1497.
68. Hanvey, J.C., Peffer, N.J., Bisi, J.E. et al., Antisense and antigene properties of peptide nucleic acids. Science, 258 (1992) 1481.
69. Egholm, M., Buchardt, O., Christensen, L. et al., PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules (see comments). Nature, 365 (1993) 566.
70. Wittung, P., Nielsen, P.E., Buchardt, O., Egholm, M. and Norden, B., DNA-like double helix formed by peptide nucleic acid. Nature, 368 (1994) 561.
71. Demidov, V.V., Potaman, V.N., Frank-Kamenetskii, M.D. et ai., Stability of peptide nucleic acids in human serum and cellular extracts. Biochem. Pharmacol., 48 (1994) 1310.
72. Egholm, M., Buchardt, O., Nielsen, P.E. and Berg, R.H., Peptide nucleic acids (PNA). Oligonucleotide analogues with an achiral peptide backbone. J. Am. Chem. Soc., 114 (1992) 1895.
73. Igloi, G.L., Variability in the stability of DNA-peptide nucleic acid (PNA) single-base mismatched duplexes: Real-time hybridization during affinity electrophoresis in PNA-containing gels. Proc. Natl. Acad. Sci. USA, 95 (1998) 8562.
74. Wittung, P., Kajanus, J., Edwards, K. et al., Phospholipid membrane permeability of peptide nucleic acid (corrected and republished with original paging, article originally printed in FEBS Lett., 22 May 1995, 365(1) 27-9). FEBS Lett., 375 (1995) 27.
75. Noble, S.A., Bonham, M.A., Bisi, J.E. et al., Impact of biophysical parameters on the biological assessment of peptide nucleic acids, antisense inhibitors of gene expression. Drug Develop. Res., 34 (1995) 184.
76. Chinnery, P.F., Taylor, R.W., Diekert, K., Lill, R., Turnbull, D.M. and Lightowlers, R.N., Peptide nucleic acid delivery to human mitochondria. Gene Ther., 6 (1999) 1919.
77. Gray, G.D., Basu, S. and Wickstrom, E., Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3′-alkylamino oligodeoxynucleotides, 2′-O-methyl oligoribonucleotides, oligodeoxynucleoside methyl-phosphonates, and peptide nucleic acids. Biochem. Pharmacol., 53 (1997) 1465.
78. Sei, S., Yang, Q.E., O'Neill, D., Yoshimura, K., Nagashima, K. and Mitsuya, H., Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J. Virol., 74 (2000) 4621.
79. Eraser, G.L., Holmgren, J., Clarke, P.B. and Wahlestedt, C., Antisense inhibition of delta-opioid receptor gene function in vivo by peptide nucleic acids. Mol. Pharmacol., 57 (2000) 725.
80. Tyler, B.M., Jansen, K., McCormick, D.J. et al., Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression. Proc. Natl. Acad. Sci. USA, 96 (1999) 7053.
81. Bonham, M.A., Brown, S., Boyd, A.L. et al., An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucl. Acids Res. 23 (1995) 1197.
82. Shammas, M.A., Simmons, C.G., Corey, D.R. and Shmookler Reis, R.J., Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells. Oncogene, 18 (1999) 6191.
83. Wang, G., Xu, X., Pace, B. et al., Peptide nucleic acid (PNA) binding-mediated induction of human gamma-globin gene expression. Nucl. Acids Res., 27 (1999) 2806.
84. Mayhood, T., Kaushik, N., Pandey, P.K., Kashanchi, F., Deng, L. and Pandey, V.N., Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element. Biochemistry, 39 (2000) 11532.
85. Gottlinger, H.G., Dorfman, T., Sodroski, J.G. and Haseltine, W.A., Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc. Natl. Acad. Sci. USA, 88 (1991) 3195.
86. Huang, M., Orenstein, J.M., Martin, M.A. and Freed, E.O., p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J. Virol., 69 (1995) 6810.
87. Yu, X.F., Dawson, L., Tian, C.J., Flexner, C. and Dettenhofer, M., Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly. J. Virol., 72 (1998) 3412.
88. Jacks, T. and Varmus, H.E., Expression of the Rous sarcoma virus pol gene by ribosomal frameshifting. Science, 230 (1985) 1237.
89. Hizi, A., Henderson, L.E., Copeland, T.D., Sowder, R.C., Hixson, C.V. and Oroszlan, S., Characterization of mouse mammary tumor virus gag-pro gene products and the ribosomal frameshift site by protein sequencing. Proc. Natl. Acad. Sci. USA, 84 (1987) 7041.
90. Jacks, T., Townsley, K., Varmus, H.E. and Majors, J., Two efficient ribosomal frameshifting events are required for synthesis of mouse mammary tumor virus gag-related polyproteins. Proc. Natl. Acad. Sci. USA, 84 (1987) 4298.
91. Mador, N., Panet, A. and Honigman, A., Translation of gag, pro, and pol gene products of human T-cell leukemia virus type 2. J. Virol., 63 (1989) 2400.
92. Nam, S.H., Copeland, T.D., Hatanaka, M. and Oroszlan, S., Characterization of ribosomal frameshifting for expression of pol gene products of human T-cell leukemia virus type I. J. Virol., 67 (1993) 196.
93. Jacks, T., Power, M.D., Masiarz, F.R., Luciw, P.A., Barr, P.J. and Varmus, H.E., Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature, 331 (1988) 280.
94. Wilson, W., Braddock, M., Adams, S.E., Rathjen, P.D., Kingsman, S.M. and Kingsman, A.J., HIV expression strategies: Ribosomal frameshifting is directed by a short sequence in both mammalian and yeast systems. Cell, 55 (1988) 1159.
95. Kozal, M.J., Shah, N., Shen, N. et al., Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat. Med., 2 (1996) 753.
96. Lech, W.J., Wang, G., Yang, Y.L. et al., In vivo sequence diversity of the protease of human immunodeficiency virus type 1: Presence of protease inhibitor-resistant variants in untreated subjects. J. Virol., 70 (1996) 2038.
97. Barrie, K.A., Perez, E.E., Lamers, S.L. et al., Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: Amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. Virology, 219 (1996) 407.
98. Checroune, F., Yao, X.J., Gottlinger, H.G., Bergeron, D. and Cohen, E.A., Incorporation of Vpr into human immunodeficiency virus type 1: role of conserved regions within the P6 domain of Pr55gag. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol., 10 (1995) 1.
99. Lu, Y.L., Bennett, R.P., Wills, J.W., Gorelick, R. and Ratner, L., A leucine triplet repeat sequence (LXX)4 in pogag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J. Virol., 69 (1995) 6873.
100. Kondo, E. and Gottlinger, H.G., A conserved LXXLF sequence is the major determinant in p6gag required for the incorporation of human immunodeficiency virus type 1 Vpr. J. Virol., 70 (1996) 159.
101. Yoshimura, K., Kato, R., Yusa, K. et al., JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc. Natl. Acad. Sci. USA, 96 (1999) 8675.
102. Pearl, L.H. and Taylor, W.R., A structural model for the retroviral proteases. Nature, 329 (1987) 351.
103. Wlodawer, A., Miller, M., Jaskolski, M. et al., Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science, 245 (1989) 616.
104. Strickler, J.E., Gorniak, J., Dayton, B. et al., Characterization and autoprocessing of precursor and mature forms of human immunodeficiency virus type 1 (HIV 1) protease purified from Eschetichia coli. Proteins, 6 (1989) 139.
105. Rose, J.R., Salto, R. and Craik, C.S., Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions. J. Biol. Chem., 268 (1993) 11939.
106. Park, J. and Morrow, C.D., The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into viruslike particles. J. Virol., 66 (1992) 6304.
107. Smith, A.J., Srinivasakumar, N., Hammarskjold, M.L. abd Rekosh, D., Requirements for incorporation of Pr160gag-pol from human immunodeficiency virus type 1 into virus-like particles. J. Virol., 67 (1993) 2266.
108. Lee, Y.M. and Yu, X.F., Identification and characterization of virus assembly intermediate complexes in HIV-1-infected CD4+ T cells. Virology, 243 (1998) 78.
109. Lee, Y.M., Tian, C.J. and Yu, X.F., A bipartite membrane-binding signal in the human immunodeficiency virus type 1 matrix protein is required for the proteolytic processing of Gag precursors in a cell type-dependent manner. J. Virol., 72 (1998) 9061.
110. Rhee, S.S. and Hunter, E., Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids. J. Virol., 61 (1987) 1045.
111. Gottlinger, H.G., Sodroski, J.G. and Haseltine, W.A., Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA, 86 (1999) 5781.
112. Bryant, M. and Ratner, L., Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc. Natl. Acad. Sci. USA, 87 (1990) 523.
113. Park, J. and Morrow, C.D., Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production. J. Virol., 65 (1991) 5111.
114. Karacostas, V., Wolffe, E.J., Nagashima, K., Gonda, M.A. and Moss, B., Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology, 193 (1993) 661.
115. Koppelhus, U., Zachar, V., Nielsen, P.E., Liu, X., Eugen-Olsen, J. and Ebbesen, P., Efficient in vitro inhibition of HIV-1 gag reverse transcription by peptide nucleic acid (PNA) at minimal ratios of PNA/RNA. Nucl. Acids Res., 25 (1997) 2167.
116. Boulme, F., Freund, F., Moreau, S. et al., Modified (PNA, 2′-O-methyl and phosphoramidate) anti-TAR antisense oligonucleotides as strong and specific inhibitors of in vitro HIV-1 reverse transcription. Nucl. Acids Res., 26 (1999) 5492.
117. Lee, R., Kaushik, N., Modak, M.J., Vinayak, R. and Pandey, V.N., Polyamide nucleic acid targeted to the primer binding site of the HIV-1 RNA genome blocks in vitro HIV-1 reverse transcription. Biochemistry, 37 (1998) 900.
118. Mischiati, C., Borgatti, M., Bianchi, N. et al., Interaction of the human NF-kappaB p52 transcription factor with DNA-PNA hybrids mimicking the NF-kappaB binding sites of the human immunodeficiency virus type 1 promoter. J. Biol. Chem., 274 (1999) 33114.
119. Danner, S.A., Carr, A., Leonard, J.M. et al., A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N. Engl. J. Med., 333 (1995) 1528.
120. Markowitz, M., Saag, M., Powderly, W.G. et al., A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med., 333 (1995) 1534.
121. Collier, A.C., Coombs, R.W., Schoenfeld, D.A. et al., Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N. Engl. J. Med., 334 (1996) 1011.
122. Schapiro, J.M., Winters, M.A., Stewart, F. et al., The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients (see comments). Ann. Intern. Med., 124 (1996) 1039.
123. Hammer, S.M., Squires, K.E., Hughes, M.D. et al., A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team (see comments). N. Engl. J. Med., 337 (1997) 725.
124. Gulick, R.M., Mellors, J.W., Havlir, D. et al., Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy (see comments). N. Engl. J. Med., 337 (1997) 734.
125. Summerton, J., Morpholino antisense oligomers: The case for an RNase H-independent structural type. Biochim. Biophys. Acta, 1489 (1999) 141.
126. Stein, D., Foster, E., Huang, S.B., Weller, D. and Summerton, J., A specificity comparison of four antisense types: Morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucl. Acids Drug Dev., 7 (1997) 151.
127. Summerton, J., Stein, D., Huang, S.B., Matthews, P., Weller, D. and Partridge, M., Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucl. Acids Drug Dev., 7 (1997) 63.
128. Knudsen, H. and Nielsen, P.E., Antisense properties of duplex- and triplex-forming PNAs. Nucl. Acids Res., 24 (1996) 494.
129. Gambacorti-Passerrni, C., Molognim, L., Bertazzoli, C. et al., In vitro transcription and translation inhibition by antipromyelocytic leukemia (PML)/retinoic acid receptor alpha and anti-PML peptide nucleic acid. Blood, 88 (1996) 1411.
130. Mologni, L., Marchesi, E. and Nielsen, P.E. Gambacorti-Passerini C., Inhibition of promyelocytic leukemia (pml)/retinoic acid receptor-alpha and pml expression in acute promyelocytic leukemia cells by anti-pml peptide nucleic acid. Cancer Res., 61 (2001) 5468.
131. Pooga, M., Soomets, U., Hallbrink, M. et al., Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol., 16 (1998) 857.
132. Scarfi, S., Giovine, M., Gasparini, A. et al., Modified peptide nucleic acids are internalized in mouse macrophages RAW 264.7 and inhibit inducible nitric oxide synthase. FEBS Lett., 451 (1999) 264.
133. Dias, N., Dheur, S., Nielsen, P.E. et al., Antisense PNA tridecamers targeted to the coding region of Ha-ras mRNA arrest polypeptide chain elongation. J. Mol. Biol., 294 (1999) 403.
134. Brown, S.C., Thomson, S.A., Veal, J.M. and Davis, D.G., NMR solution structure of a peptide nucleic acid complexed with RNA. Science, 265 (1994) 777.
135. Berts, L., Josey, J.A., Veal, J.M. and Jordan, S.R., A nucleic acid triple helix formed by a peptide nucleic acid-DNA complex. Science, 270 (1995) 1838.
136. Eriksson, M. and Nielsen, P.E., Solution structure of a peptide nucleic acid-DNA duplex. Nat. Struct. Biol., 3 (1996) 410.
137. Rasmussen, H., Kastrup, J.S., Nielsen, J.N., Nielsen, J.M. and Nielsen, P.E., Crystal structure of a peptide nucleic acid (PNA) duplex at 1.7 A resolution. Nat. Struct. Biol., 4 (1997) 98.
138. Bastide, L., Boehmer, P.E., Villani, G. and Lebleu, B., Inhibition of a DNA-helicase by peptide nucleic acids. Nucl. Acids Res., 27 (1999) 551.
139. Boehmer, P.E. and Lehman, I.R., Herpes simplex virus DNA replication. Annu. Rev. Biochem., 66 (1997) 347.
140. Kurg, R., Langel, U. and Ustav, M., Inhibition of the bovine papillomaviras E2 protein activity by peptide nucleic acid. Virus Res., 66 (2000) 39.
141. Spalholz, B.A., Yang, Y.C. and Howley, P.M., Transactivation of a bovine papilloma virus transcriptional regulatory element by the E2 gene product. Cell, 42 (1985) 183.
142. Tackett, A.J., Wei, L., Cameron, C.E. and Raney, K.D., Unwinding of nucleic acids by HCV NS3 helicase is sensitive to the structure of the duplex. Nucl. Acids Res., 29 (2001) 565.
143. Stock, R.P., Olvera, A., Sanchez, R. et al., Inhibition of gene expression in Entamoeba histolytica with antisense peptide nucleic acid oligomers. Nat. Biotechnol., 19 (2001) 231.
144. Good, L. and Nielsen, P.E., Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. Nat. Biotechnol., 16 (1998) 355.
145. Good, L., Awasthi, S.K., Dryselius, R., Larsson, O. and Nielsen, P.E., Bactericidal antisense effects of peptide-PNA conjugates. Nat. Biotechnol., 19 (2001) 360.
146. Pooga, M., Hallbrink, M., Zorko, M. and Langel, U., Cell penetration by transportas FASEB J., 12 (1998) 67.
147. Pooga, M., Lindgren, M., Hallbrink, M., Brakenhielm, E. and Langel, U., Galanin-based peptides, galparan and transportan, with receptor-dependent and independent activities. Ann. N. Y. Acad. Sci., 863 (1998) 450.
148. Derossi, D., Calvet, S., Trembleau, A., Brunissen, A., Chassaing, G. and Prochiantz, A., Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J. Biol. Chem., 271 (1996) 18188.
149. Villa, R., Folini, M., Lualdi, S., Veronese, S., Daidone, M.G. and Zaffaroni, N., Inhibition of telomerase activity by a cell-penetrating peptide nucleic acid construct in human melanoma cells. FEBS Lett., 473 (2000) 241.
150. Feng, J., Funk, W.D., Wang, S.S. et al., The RNA component of human telomerase. Science, 269 (1995) 1236.
151. Brown, D., Kogan, S., Lagasse, E. et al., A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA, 94 (1997) 2551.
152. Hamilton, S.E., Simmons, C.G., Kathiriya, I.S. and Corey, D.R., Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem. Biol., 6 (1999) 343.
153. Kalderon, D., Roberts, B.L., Richardson, W.D. and Smith, A.E., A short amino acid sequence able to specify nuclear location. Cell, 39 (1984) 499.
154. Cutrona, G., Carpaneto, E.M., Ulivi, M. et al., Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. Nat. Biotechnol., 18 (2000) 300.
155. Boffa, L.C., Scarfi, S., Mariani, M.R. et al., Dihydrotestosterone as a selective cellular/nuclear localization vector for anti-gene peptide nucleic acid in prostatic carcinoma cells. Cancer Res., 60 (2000) 2258.
156. Basu, S. and Wickstrom, E., Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake. Bioconjug. Chem., 8 (1997) 481.
157. Penichet, M.L., Kang, Y.S., Pardridge, W.M., Morrison, S.L. and Shin, S.U., An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: Initial applications in anti-HIV antisense drug delivery to the brain. J. Immunol., 163 (1999) 4421.
158. Pardridge, W.M., Boado, R.J. and Kang, Y.S., Vector-mediated delivery of a polyamide ('peptide') nucleic acid analogue through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci. USA, 92 (1995) 5592.
159. Rezaei, K., Xu, I.S., Wu, W.P. et al., Intrathecal administration of PNA targeting galanin receptor reduces galanin-mediated inhibitory effect in the rat spinal cord. Neuroreport, 12 (2001) 317.
160. Barre-Sinoussi, F., Chermann, J.C., Rey, F. et al., Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 220 (1983) 868.
161. Gallo, R.C., Sarin, P.S., Gelmann, E.P. et al., Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science, 220 (1983) 865.
162. Gao, F., Baues, E., Robertson, D.L. et al., Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature, 397 (1999) 436.
163. Dalgleish, A.G., Beverley, P.C., Clapham, P.R., Crawford, D.H., Greaves, M.F. and Weiss, R.A., The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature, 312 (1984) 763.
164. Klatzmann, D., Champagne, E., Chamaret, S. et al., T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature, 312 (1984) 767.
165. Alkhatib, G., Combadiere, C., Broder, C.C. et al., CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science, 272 (1996) 1955.
166. Bleui, C.C., Parzan, M., Choe, H. et al., The lymphocyte chemoattractant
167. Deng, H., Liu, R., Ellmeier, W. et al., Identification of a major co-receptor for primary isolates of HIV-1 (see comments). Nature, 381 (1996) 661.
168. Dragic, T., Litwin, V., Allaway, G.P. et al., HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 (see comments). Nature, 381 (1996) 667.
169. Feng, Y., Broder, C.C., Kennedy, P.E. and Berger, E.A., HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor (see comments). Science, 272 (1996) 872.
170. Tang, H., Kuhen, K.L. and Wong-Staal, F., Lentivirus replication and regulation. Annu. Rev. Genet., 33 (1999) 133.
171. McCune, J.M., The dynamics of CD4+ T-cell depletion in HIV disease. Nature, 410 (2001) 974.
172. O'Brien, S.J. and Moore, J.P., The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol. Rev., 177 (2000) 99.